Sattva S. Neelapu, MD | Authors

Articles

Long-Term Follow-Up Results From the ZUMA-1 Trial in Non-Hodgkin Lymphoma

February 23, 2018

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses long-term findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory aggressive non-Hodgkin lymphoma.

Results of the ZUMA-1 Trial Exploring KTE-C19 in NHL

May 19, 2017

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.